Published: 2 March 2023


Recent approvals: new active ingredients or new indications

Published: 2 March 2023
Prescriber Update 44(1): 15
March 2023

For the period 16 October 2022 to 15 January 2023.

Recent approvals of medicines with new active ingredients

Trade name
(active ingredient)
Dose form and strength(s) Therapeutic area
(voretigene neparvovec)
Concentrate for injection: 5x10^12 VP/mL Inherited retinal dystrophy caused by pathological biallelic RPE65 mutations

Approved medicines with new indications

Trade Name
(active ingredient)
Dose form and strength(s) New therapeutic area(s)
Powder for injection: 100 mg/mL Solution for injection (pre-filled pen and pre-filled syringe): 100 mg/mL Chronic rhinosinusitis with nasal polyps
Hypereosinophilic syndrome

See the Medsafe website for:

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /